ARYx Therapeutics, of Fremont, Calif., appointed Herm Rosenman to its board.
Athenagen Inc., of South San Francisco, appointed Barr Dolan to its board.
Avalon Pharmaceuticals Inc., of Germantown, Md., appointed William Washecka to its board.
Avanir Pharmaceuticals, of San Diego, appointed Matthew Ruth vice president of sales.
Biotage, of Uppsala, Sweden, appointed Torben Jorgensen CEO.
Catalyst Biosciences Inc., of South San Francisco, appointed Nassim Usman CEO.
Ceragenix Pharmaceuticals Inc., of Denver, appointed Donald Leung to its scientific advisory board.
CyGenics Ltd., of Sydney, Australia, appointed Alberto Bautista to its board.
Dendreon Corp., of Seattle, named Ernest Bognar general manager of its new manufacturing facility in Hanover, N.J.
Dynavax Technologies Corp., of Berkeley, Calif., appointed Arnold Oronsky chairman of its board.
Genesis Bioventures Inc., of New York, appointed Lou Lome a scientific adviser.
Genzyme Corp., of Cambridge, Mass., appointed Richard Syron to its board.
GlycoFi, of Lebanon, N.H., said Gerald Fink joined its scientific advisory board.
ICo Therapeutics Inc., of Vancouver, British Columbia, appointed Alan Bird to its strategic advisory team.
ImmuneRegen BioSciences Inc., of Scottsdale, Ariz., appointed Kelly McQueen to its drug development advisory board.
Isotechnika Inc., of Edmonton, Alberta, appointed Franklin Berger to its board.
IsoTis OrthoBiologics, of Lausanne, Switzerland, appointed Alan Donze vice president of sales.
Keryx Biopharmaceuticals Inc., of New York, appointed Ronald Renaud senior vice president, chief financial officer and treasurer.
Kosan Biosciences Inc., of Hayward, Calif., promoted Peter Licari to senior vice president, manufacturing and operations, and Pieter Timmermans to senior vice president, drug discovery and preclinical development.
Labopharm Inc., of Laval, Quebec, appointed Santo Costa to its board.
Life Therapeutics Ltd., of Frenchs Forest, Australia, appointed Jesse McCorvey vice president, corporate communications.
